International WELL Building Institute Opens Enrollment for WELL Health-Safety Rating In Response to COVID-19 With Significant Early Adoption
8.7.2020 20:18:00 EEST | Business Wire | Press release
The International WELL Building Institute (IWBI) announced that enrollment has opened today for the WELL Health-Safety Rating for Facility Operations and Management, with more than 100 organizations and real estate portfolios across the globe already enrolled. Organizations across a wide range of industries and geographic locations have responded swiftly to implement the program’s science-backed guidance as they seek to instill confidence and trust among their staff, stakeholders and the broader community.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200708005768/en/
The WELL Health-Safety Rating is an evidence-based, third-party verified rating for all new and existing building and space types focused on operational policies, maintenance protocols, emergency plans and stakeholder engagement strategies to help organizations prepare their spaces for re-entry in a post COVID-19 environment.
Adapted from features in the WELL Building Standard (WELL) that focus on facilities, maintenance and operations, the WELL Health-Safety Rating is designed to guide and empower the actions of large and small businesses alike in taking the necessary steps to prioritize the health and safety of their staff, visitors and stakeholders. It also serves as an annual process that supports efforts to promote the long-term health and safety of people.
“We’re all eager to get back to our workplaces, back to school, back to traveling, dining, and cheering on our favorite teams and performers,” said IWBI Chairman and CEO Rick Fedrizzi. “As organizations across the globe respond to the COVID-19 crisis through changes in policies and protocols, the WELL Health-Safety Rating delivers the evidence-based health strategies required to help them safely reopen with the confidence and integrity provided by third-party verification.”
Created by IWBI, the WELL Health-Safety Rating is informed by guidance developed by the World Health Organization (WHO), U.S. Centers for Disease Control and Prevention (CDC), global disease control and prevention centers and emergency management agencies, recognized standard-making bodies, such as ASTM International and ASHRAE, and leading academic and research institutions. IWBI has leveraged insights from its Task Force on COVID-19, established at the outset of the pandemic to help business and building leaders integrate actionable insights and proven strategies in the fight against COVID-19 and other respiratory infections.
“This moment has highlighted the critical role that buildings, and those that own and operate them, can play in supporting people’s health, safety and well-being,” said IWBI President Rachel Gutter. “This new rating aims to meet the urgent need to deliver high health and safety standards in all of the spaces we occupy. While longer term design strategies are important in reducing the risks of infectious disease spread, this rating focuses on strategies that can be implemented immediately to address acute threats, using our buildings and spaces as a first line of defense in the fight against COVID-19.”
Demonstrating thought leadership and commitment to the health and safety of their stakeholder communities, the following leading organizations are among the first that have enrolled to achieve the WELL Health-Safety Rating:
|
ACCIONA SA |
|
Adventist Health |
|
Aedifica |
|
Alpin Limited (Masdar City) |
|
American Savings Bank |
|
Bartra Capital Property |
|
CAMCO Management Co. |
|
Carrier |
|
Catalyst Partners |
|
CBD Z03 |
|
CBRE Barcelona |
|
CBRE Madrid |
|
China Overseas Office Capital |
|
Cleveland Clinic Courts / Cleveland Cavaliers |
|
Climate Change Arena |
|
Community Investment Strategies, Inc |
|
CR Land |
|
Deerns |
|
Delos China |
|
Delos Living LLC |
|
Delta Electronics, Inc. |
|
Denholtz Properties |
|
Department of Earth System Science, Tsinghua University |
|
Empire State Realty Trust |
|
EMSI |
|
GFP Real Estate |
|
Ghelamco Poland Sp. z o.o. |
|
Glenstar |
|
GuocoLand China Ltd. |
|
HBMSU |
|
Heitman |
|
Herman Miller Group |
|
Hornets Sports & Entertainment - Spectrum Center |
|
HRO |
|
Infancix Co., Ltd |
|
International Commerce Centre |
|
International WELL Building Institute PBC |
|
Ivanhoé Cambridge |
|
Jiahui Health |
|
JLL |
|
Karisma Hotels and Resorts |
|
Kilroy Realty Corporation |
|
Kimball |
|
Laguna |
|
Lendlease Australia Office Portfolios: Australian Prime Property Fund Commercial, Lendlease International Towers Sydney Trust and Lendlease One International Towers Sydney Trust |
|
Lincoln Property Company |
|
M Moser Associates |
|
Mace |
|
Maple Leaf Sports & Entertainment (MLSE), which encompasses the Toronto Maple Leafs (NHL), Toronto Raptors (NBA), Toronto FC (MLS), & Toronto Argonauts (CFL) |
|
Menarco Development Corporation |
|
Milliken & Company |
|
ML7 |
|
Montage International |
|
Moody Center
|
|
New Belmont Arena |
|
New York Yankees |
|
Oak View Group |
|
Out of the Box Ventures |
|
Overbury Morgan Lovell |
|
OVG Arena Alliance & Stadium Alliance |
|
OVG Facilities |
|
Pacers Sports & Entertainment: Bankers Life Fieldhouse (Indianapolis, Ind.) |
|
Pacers Sports & Entertainment: St. Vincent Center/Indiana Pacers Training Facility (Indianapolis, Ind.) |
|
Parmenter Realty Partners |
|
Phipps Conservatory and Botanical Gardens |
|
RMZ Corp |
|
Rocket Mortgage FieldHouse / Cleveland Cavaliers & Cleveland Monsters |
|
Royal Albert Hall |
|
Rubrik India Pvt Ltd |
|
Savanna |
|
Serpentini Auto Group |
|
Shanghai Landleaf Architecture Technology Co. Ltd |
|
ShouGang Group |
|
Sino-Ocean |
|
Space Matrix Design Consultants Pvt. Ltd
|
|
TAIPEI 101 Tower |
|
Taiwan Architecture & Building Center |
|
Teknion |
|
The Florida Panthers and BB&T Center |
|
The Forestias |
|
The Related Group |
|
Thornton Tomasetti |
|
TITANIUM OFFICE SOLUTIONS MEXICO |
|
Uber Technologies, Inc. |
|
UltraStar Harrah’s Ak Chin Resort Maricopa, Az. |
|
United Center |
|
Webster Bank Arena |
|
Wells Fargo Center, Philadelphia, Pa. |
|
Wolfgang Puck Fine Dining Group |
|
Woonerf Inc. |
|
Yuexiu Commercial |
Upon achieving the designation, IWBI will issue the building or space a WELL Health-Safety seal.
The WELL Health-Safety Rating draws on principles established by IWBI’s WELL Building Standard, the premier standard for healthy real estate, which has surpassed 590 million square feet in registrations across 62 countries since inception. The WELL Building movement has been further amplified by over 12,000 WELL Accredited Professionals (APs) and registrants across the globe.
To learn more about the WELL Health-Safety Rating and to enroll, please visit www.wellcertified.com/health-safety.
About the International WELL Building Institute
The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings, communities and organizations in ways that help people thrive. The WELL v2 pilot is the latest version of its popular WELL Building Standard (WELL), and the WELL Community Standard pilot is a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI mobilizes the wellness community through management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness everywhere. IWBI is a participant of the United Nations Global Compact, the world’s largest corporate citizenship initiative, and helps companies advance the UN Sustainable Development Goals (SDGs) through the use of WELL. More information on WELL can be found here.
International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL, WELL Portfolio, The WELL Conference, the WELL Community Standard, WELL Health-Safety Rating and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200708005768/en/
Contact information
Media:
Judith Webb
media@wellcertified.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 14:42:00 EEST | Press release
Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429263104/en/ • Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn • Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditions • Transaction expected to close in
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 14:00:00 EEST | Press release
Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S. Marines. The Next Generation EW prototype is centered on the C5ISR Modular Open Suite of S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 14:00:00 EEST | Press release
Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means our partners can choose the networks that best fit their needs, while relying on Visa to provide
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indication. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “HERIZON‑GEA‑01 has the potential to shift the treatment paradigm in this historically difficult-to-treat disease, with the TEVIMBRA-containing arm demonstrating an unprecedented 26-month survival benefit. The FDA’s Prior
European Commission (EC) Approves Henlius and Organon’s POHERDY ® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 12:30:00 EEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
